Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-27 · 1381 Präparate · 72104 Quellenpassagen · 204 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Clopidogrel ratiopharm
Clopidogrel ratiopharm 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-222537 · Präparat HOS-217040
Less pronounced reductions of metabolite exposure has been observed with pantoprazole or
lansoprazole.
The plasma concentrations of the active metabolite was 20% reduced (loading dose) and 14% reduced
(maintenance dose) during concomitant treatment with pantoprazole 80 mg once daily. This was
associated with a reduction of the mean inhibition of platelet aggregation by 15% and 11%,
respectively. These results indicate that clopidogrel can be administered with pantoprazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167) clopidogrel (HOS-087927)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-03-26T01:00:00Z · SHA-256 bb1e41aa3fcc130d790cea18e2c1ae62fcbdb4cf2e59a3e8c2e4a3977273809f · Passage 8741959ca26ef1991d9f10cb8dc0408f0677a8d230580e185084c52e76eb6108 · Zeichen 5231–5708 im Abschnitt
Wechselwirkungen · Nerlynx
Nerlynx 40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-223080 · Präparat HOS-217118
7
administration with proton pump inhibitors (PPIs) is not recommended (e.g. omeprazole or
lansoprazole) (see sections 4.4 and 5.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-27T08:41:00Z · SHA-256 c07f71eca240457f975efbcd55ec4c9f4b5a19351213381f49a862d1cd7a5f7c · Passage 00f684719b48363e50ace52a580d9c1be753a9fd5df1360b0454f501008431c5 · Zeichen 1935–2068 im Abschnitt
Wechselwirkungen · Ivabradine Zentiva
Ivabradine Zentiva 5 mg film-coated tablets Ivabradine Zentiva 7.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-223987 · Präparat HOS-217260
Other concomitant use
Specific interaction studies have shown no clinically significant effect of the following medicinal products
on pharmacokinetics and pharmacodynamics of ivabradine: proton pump inhibitors (omeprazole,
lansoprazole), sildenafil, HMG-CoA reductase inhibitors (simvastatin), dihydropyridine calcium channel
blockers (amlodipine, lacidipine), digoxin and warfarin. In addition there was no clinically significant
effect of ivabradine on the pharmacokinetics of simvastatin, amlodipine, lacidipine, on the
pharmacokinetics and pharmacodynamics of digoxin, warfarin and on the pharmacodynamics of aspirin.
In pivotal phase III clinical trials the following medicinal products were routinely combined
with ivabradine with no evidence of safety concerns: angiotensin converting enzyme inhibitors,
angiotensin II antagonists, beta-blockers, diuretics, anti-aldosterone agents, short and long acting nitrates,
HMG CoA reductase inhibitors, fibrates, proton pump inhibitors, oral antidiabetics, aspirin and other anti-
platelet medicinal products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) angiotensin II (HOS-085480) aspirin (HOS-111273) lacidipine (HOS-113865) aldosterone (HOS-086926) amlodipine (HOS-086287) simvastatin (HOS-086158) digoxin (HOS-086172) calcium (HOS-085615) sildenafil (HOS-086162) warfarin (HOS-085950) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-17T11:53:00Z · SHA-256 cf8394b598d7771cbf7fe0c054e2454bdb3007a0414d4f1d023d9469ba7ec0f4 · Passage 92e39709d0f91b2b54c28de867f62de0fa44dd3b0d21219e06b9692209e381bd · Zeichen 3725–4783 im Abschnitt
Gegenanzeigen · Odefsey
Odefsey 200 mg/25 mg/25 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 3
HOS-224386 · Präparat HOS-217308
• carbamazepine, oxcarbazepine, phenobarbital, phenytoin
• rifabutin, rifampicin, rifapentine
• omeprazole, esomeprazole, dexlansoprazole, lansoprazole, pantoprazole, rabeprazole
• dexamethasone (oral and parenteral doses), except as a single dose treatment
• St. John’s wort (Hypericum perforatum)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) rabeprazole (HOS-114843) esomeprazole (HOS-087944) phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) pantoprazole (HOS-085167) dexamethasone (HOS-084535) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) dexlansoprazole (HOS-138501) phenytoin (HOS-084531) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-02-20T11:15:00Z · SHA-256 301500f7e0409802f65079ff3319433bf96c2efc5c6741c9a9914a3ce67120ca · Passage dab436617f78f90f996cf4e07efe5a34e1508575569c7aed6b2c46a2b5cbfdaf · Zeichen 397–715 im Abschnitt
Wechselwirkungen · Odefsey
Odefsey 200 mg/25 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-224442 · Präparat HOS-217308
Rilpivirine:
AUC: ↓ 40%
Cmin: ↓ 33%
Cmax: ↓ 40%
Reduced absorption, increase in
gastric pH
Lansoprazole Interaction not studied with any of Co-administration is
Rabeprazole the components of Odefsey. contraindicated.
Pantoprazole Significant decreases in rilpivirine
Esomeprazole plasma concentrations are expected
Dexlansoprazole (reduced absorption, increase in
gastric pH).
HERBAL PRODUCTS
St. John’s wort (Hypericum Interaction not studied with any of Co-administration is
perforatum) the components of Odefsey. contraindicated.
Co-administration may cause
significant decreases in the plasma
concentrations of rilpivirine
(induction of CYP3A) and tenofovir
alafenamide (induction of P-gp).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) tenofovir (HOS-088083) rabeprazole (HOS-114843) esomeprazole (HOS-087944) pantoprazole (HOS-085167) dexlansoprazole (HOS-138501)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-02-20T11:15:00Z · SHA-256 301500f7e0409802f65079ff3319433bf96c2efc5c6741c9a9914a3ce67120ca · Passage 757729aeefad8e843193a1b45e6836d8a10d98474e9aa45f9fe01f823805b308 · Zeichen 17567–18869 im Abschnitt
Wechselwirkungen · Ivabradine Anpharm
Ivabradine Anpharm 5 mg film-coated tablets Ivabradine Anpharm 7.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-224799 · Präparat HOS-217356
Other concomitant use
Specific interaction studies have shown no clinically significant effect of the following medicinal
products on pharmacokinetics and pharmacodynamics of ivabradine: proton pump inhibitors
(omeprazole, lansoprazole), sildenafil, HMG CoA reductase inhibitors (simvastatin), dihydropyridine
calcium channel blockers (amlodipine, lacidipine), digoxin and warfarin. In addition there was no
7
Classified as confidential by the European Medicines Agency
clinically significant effect of ivabradine on the pharmacokinetics of simvastatin, amlodipine,
lacidipine, on the pharmacokinetics and pharmacodynamics of digoxin, warfarin and on the
pharmacodynamics of aspirin.
In pivotal phase III clinical trials the following medicinal products were routinely combined with
ivabradine with no evidence of safety concerns: angiotensin converting enzyme inhibitors, angiotensin
II antagonists, beta-blockers, diuretics, anti-aldosterone agents, short and long acting nitrates, HMG
CoA reductase inhibitors, fibrates, proton pump inhibitors, oral antidiabetics, aspirin and other anti-
platelet medicinal products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) aspirin (HOS-111273) lacidipine (HOS-113865) aldosterone (HOS-086926) amlodipine (HOS-086287) simvastatin (HOS-086158) digoxin (HOS-086172) calcium (HOS-085615) sildenafil (HOS-086162) warfarin (HOS-085950) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T10:15:00Z · SHA-256 0c28ae1bf473433869a5a29b3da9716c1f9460c431989f9bd819d8abd0b1b564 · Passage 981400cbe48189f25a94505c4284bf661c75e6dac86c92511a9ec90350f4201a · Zeichen 3819–5014 im Abschnitt
Wechselwirkungen · Ivabradine Accord
Ivabradine Accord 5 mg film-coated tablets Ivabradine Accord 7.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-225248 · Präparat HOS-217416
Other concomitant use
Specific interaction studies have shown no clinically significant effect of the following medicinal
products on pharmacokinetics and pharmacodynamics of ivabradine: proton pump inhibitors
(omeprazole, lansoprazole), sildenafil, HMG CoA reductase inhibitors (simvastatin), dihydropyridine
calcium channel blockers (amlodipine, lacidipine), digoxin and warfarin. In addition there was no
clinically significant effect of ivabradine on the pharmacokinetics of simvastatin, amlodipine,
lacidipine, on the pharmacokinetics and pharmacodynamics of digoxin, warfarin and on the
pharmacodynamics of acetylsalicylic acid.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) lacidipine (HOS-113865) amlodipine (HOS-086287) simvastatin (HOS-086158) digoxin (HOS-086172) calcium (HOS-085615) sildenafil (HOS-086162) warfarin (HOS-085950) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-09-06T15:00:00Z · SHA-256 2b81b21fb62f949b67b10250842297003ca287e30d8c0263dd11a89b0e08f230 · Passage 6278e689f99aeb7cb0963eea77ba3aeaf53d9596689b6f784c1a74069340c708 · Zeichen 3719–4353 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 17–18
HOS-138500 · Präparat HOS-098200
17
PROTON PUMP INHIBITORS
Dexlansoprazole Based on theoretical Symtuza can be co-administered
Esomeprazole considerations, no mechanistic with proton pump inhibitors
Lansoprazole interaction is expected. without dose adjustments.
Omeprazole
Pantoprazole
Rabeprazole
SEDATIVES/HYPNOTICS
Buspirone Based on theoretical considerations Clinical monitoring is
Clorazepate DRV/COBI is expected to increase recommended when
Diazepam these sedative/hypnotic plasma co-administering Symtuza with
Estazolam concentrations. these sedatives/hypnotics and a
Flurazepam (CYP3A inhibition) lower dose of the
Midazolam (parenteral) sedative/hypnotic should be
Zolpidem considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) rabeprazole (HOS-114843) estazolam (HOS-086165) esomeprazole (HOS-087944) pantoprazole (HOS-085167) clorazepate (HOS-086164) diazepam (HOS-085904) zolpidem (HOS-086327) buspirone (HOS-086325) dexlansoprazole (HOS-138501) flurazepam (HOS-086166) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage d66918b1ab817bed50d64727b6ed8e70c3661e6e6c213975acff37740c998350 · Zeichen 42940–44015 im Abschnitt
Gegenanzeigen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 3
HOS-138646 · Präparat HOS-098240
Co-administration with the following medicinal products:
- fampridine (also known as dalfampridine);
- carbamazepine, oxcarbazepine, phenobarbital, phenytoin;
- rifampicin, rifapentine;
- proton pump inhibitors, such as omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole;
- systemic dexamethasone, except as a single dose treatment;
- St John's wort (Hypericum perforatum).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) rabeprazole (HOS-114843) esomeprazole (HOS-087944) phenobarbital (HOS-085617) carbamazepine (HOS-085618) pantoprazole (HOS-085167) dexamethasone (HOS-084535) dalfampridine (HOS-124191) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage 9174ae712b2df8e1079fcece69b45cda4a99f625ece4256ab47b980d2ebdfffe · Zeichen 94–482 im Abschnitt
Wechselwirkungen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-138687 · Präparat HOS-098240
Fluconazole Rilpivirine ↑
Itraconazole Not studied. May cause an
Isavuconazole increase in the
Posaconazole plasma concentrations of
Voriconazole/ rilpivirine
Rilpivirine (inhibition of CYP3A
enzymes).
Herbal products
St. John’s wort/ Dolutegravir Co-administration may cause significant decreases
Dolutegravir Not studied. Decrease in rilpivirine plasma concentrations. This may
expected due to induction of result in loss of therapeutic effect of
UGT1A1 and CYP3A dolutegravir/rilpivirine. Co-administration of
enzymes, a similar reduction dolutegravir/rilpivirine with St. John’s wort is
in exposure as observed contraindicated (see section 4.3).
with carbamazepine is
expected.
St. John’s wort/
Rilpivirine Rilpivirine
Not studied. Significant
decreases in rilpivirine
plasma concentrations are
expected
(induction of CYP3A
enzymes).
Potassium channel blockers
Fampridine (also Fampridine Co-administration of dolutegravir has the potential
known as to cause seizures due to increased fampridine
dalfampridine)/ plasma concentration via inhibition of OCT2
Dolutegravir transporter; co-administration has not been studied.
Fampridine co-administration with
dolutegravir/rilpivirine is contraindicated (see
section 4.3).
Proton pump inhibitors
Omeprazole Dolutegravir Co-administration may significantly decrease
Lansoprazole (Not studied) rilpivirine plasma concentration. This may result in
Rabeprazole loss of therapeutic effect of
Pantoprazole dolutegravir/rilpivirine. Co-administration of
Esomeprazole/ dolutegravir/rilpivirine with proton pump
Dolutegravir inhibitors is contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) isavuconazole (HOS-085186) rabeprazole (HOS-114843) esomeprazole (HOS-087944) carbamazepine (HOS-085618) pantoprazole (HOS-085167) voriconazole (HOS-084524) itraconazole (HOS-084516) dalfampridine (HOS-124191) fluconazole (HOS-087945) potassium (HOS-086929) posaconazole (HOS-085622) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage a31f2642580d15bddbc8923f96075e21d607d5433d01b4ad8e687e24731abda2 · Zeichen 12137–14762 im Abschnitt
Wechselwirkungen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-138690 · Präparat HOS-098240
Lansoprazole Rilpivirine
Rabeprazole Not studied. Significant
Pantoprazole decreases in rilpivirine
Esomeprazole/ plasma concentrations are
Rilpivirine expected
(reduced absorption due to
gastric pH increase).
H2-recepter antagonists
Famotidine Dolutegravir The combination of dolutegravir/rilpivirine and
Cimetidine (Not studied) H2-receptor antagonists should be used with
Nizatidine particular caution. Only H2-receptor antagonists
Ranitidine/ that can be dosed once daily should be used.
Dolutegravir
H2-receptor antagonists should be taken well
Famotidine/ Rilpivirine separated in time from the administration of
Rilpivirine1,2 AUC ↓ 9% dolutegravir/rilpivirine (minimum 4 hours after or
40 mg single dose Cmin NA 12 hours before)
taken 12 hours before Cmax ↔
rilpivirine
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) nizatidine (HOS-138496) rabeprazole (HOS-114843) esomeprazole (HOS-087944) cimetidine (HOS-085835) pantoprazole (HOS-085167) famotidine (HOS-112087) ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage ea9028ca3d0fa3d4c503c1b3af0236bf88a7f581c3738dab63a63d57e45bc310 · Zeichen 15199–16371 im Abschnitt
Wechselwirkungen · Tacforius
Tacforius 0.5 mg prolonged-release hard capsules Tacforius 1 mg prolonged-release hard capsules Tacforius 3 mg prolonged-release hard capsules Tacforius 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 11–12
HOS-139158 · Präparat HOS-098290
11
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Strong CYP3A4 inhibitors: May increase tacrolimus whole It is recommended that
antifungal agents (e.g., blood trough concentrations and concomitant use should be
ketoconazole, itraconazole, increase the risk of serious adverse avoided. If co-administration
posaconazole, voriconazole), reactions (e.g., nephrotoxicity, of a strong CYP3A4 inhibitor
the macrolide antibiotics (e.g., neurotoxicity, QT prolongation) is unavoidable, consider
telithromycin, which requires close monitoring omitting the dose of tacrolimus
troleandomycin, (see section 4.4). the day the strong CYP3A4
clarithromycin, josamycin), Rapid and sharp increases in inhibitor is initiated. Reinitiate
HIV protease inhibitors (e.g., tacrolimus levels may occur, as tacrolimus the next day at a
ritonavir, nelfinavir, early as within 1-3 days after co- reduced dose based on
saquinavir), HCV protease administration, despite immediate tacrolimus blood
inhibitors (e.g., telaprevir, reduction of tacrolimus dose. concentrations. Changes in
boceprevir, and the Overall tacrolimus exposure may both tacrolimus dose and/or
combination of ombitasvir increase >5 fold. When ritonavir dosing frequency should be
and paritaprevir with combinations are co-administered, individualized and adjusted as
ritonavir, when used with and tacrolimus exposure may increase needed based on tacrolimus
without dasabuvir), >50 fold. Nearly all patients may trough concentrations, which
nefazodone, the require a reduction in tacrolimus should be assessed at initiation,
pharmacokinetic enhancer dose and temporary interruption of monitored frequently
cobicistat, and the kinase tacrolimus may also be necessary. throughout (starting within the
inhibitors idelalisib, ceritinib. The effect on tacrolimus blood first few days) and re-
Strong interactions have also concentrations may remain for evaluated on and after
been observed with the several days after co-administration completion of the CYP3A4
macrolide antibiotic is completed. inhibitor. Upon completion,
erythromycin. appropriate dose and dosing
frequency of tacrolimus should
be guided by tacrolimus blood
concentrations. Monitor renal
function, ECG for QT
prolongation, and other side
effects closely.
Moderate or weak CYP3A4 May increase tacrolimus whole Monitor tacrolimus whole
inhibitors: blood trough concentrations and blood trough concentrations
antifungal agents (e.g., increase the risk of serious adverse frequently, starting within the
fluconazole, isavuconazole, reactions (e.g., neurotoxicity, QT first few days of co-
clotrimazole, miconazole), the prolongation) (see section 4.4). A administration. Reduce
macrolide antibiotics (e.g., rapid increase in tacrolimus level tacrolimus dose if needed (see
azithromycin), calcium may occur. section 4.2). Monitor renal
channel blockers (e.g., function, ECG for QT
nifedipine, nicardipine, prolongation, and other side
diltiazem, verapamil), effects closely.
amiodarone, danazol,
ethinylestradiol, lansoprazole,
omeprazole, the HCV
antivirals elbasvir/grazoprevir
and glecaprevir/pibrentasvir,
the CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib, crizotinib
and imatinib and (Chinese)
herbal remedies containing
extracts of Schisandra
sphenanthera
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) ceritinib (HOS-086215) josamycin (HOS-113844) diltiazem (HOS-086288) nefazodone (HOS-084519) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) nelfinavir (HOS-084520) nicardipine (HOS-090619) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) crizotinib (HOS-116818) cobicistat (HOS-088111) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) calcium (HOS-085615) imatinib (HOS-110212) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) grazoprevir (HOS-108815) itraconazole (HOS-084516) saquinavir (HOS-084522) danazol (HOS-085473) fluconazole (HOS-087945) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) amiodarone (HOS-085596) paritaprevir (HOS-110301) tyrosine (HOS-108875) posaconazole (HOS-085622) nilotinib (HOS-086218) miconazole (HOS-115630) idelalisib (HOS-116811) omeprazole (HOS-085912) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-08T17:10:00Z · SHA-256 bf71e479a3104e9d8dd9aede574f2baf87c2d76cd8cc9266ee2ef92ed475dc55 · Passage 68eefd97f11d29951c1cb7e82fce1c09e7dec9a4f694ee7101cde8ef1e7bf3ae · Zeichen 3968–8645 im Abschnitt
Wechselwirkungen · Prevymis
PREVYMIS 240 mg film-coated tablets PREVYMIS 480 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-139790 · Präparat HOS-098408
Medicinal products metabolised by CYP2C9 and/or CYP2C19
Co-administration of letermovir with voriconazole (a CYP2C19 substrate) results in significantly
decreased voriconazole plasma concentrations, indicating that letermovir is an inducer of CYP2C19.
CYP2C9 is likely also induced. Letermovir has the potential to decrease the exposure of CYP2C9
and/or CYP2C19 substrates potentially resulting in subtherapeutic levels.
-Examples of such medicinal products include warfarin, voriconazole, diazepam, lansoprazole,
omeprazole, esomeprazole, pantoprazole, tilidine, tolbutamide (see Table 1).
The effect is expected to be less pronounced for oral letermovir without cyclosporine, than intravenous
letermovir with or without cyclosporine, or oral letermovir with cyclosporine. This needs to be
considered when the letermovir regimen is changed during treatment with a CYP2C9 or CYP2C19
substrate. See also general information on induction above regarding time courses of the interaction.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) esomeprazole (HOS-087944) pantoprazole (HOS-085167) diazepam (HOS-085904) voriconazole (HOS-084524) tilidine (HOS-139791) cyclosporine (HOS-084512) warfarin (HOS-085950) tolbutamide (HOS-086568) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage 36624c857b768dba23b02c3d2de829eb4507276a1d9b77109a781ba60215e541 · Zeichen 7001–7985 im Abschnitt
Wechselwirkungen · Prevymis
PREVYMIS 240 mg concentrate for solution for infusion PREVYMIS 480 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 40
HOS-139863 · Präparat HOS-098408
Medicinal products metabolised by CYP2C9 and/or CYP2C19
Co-administration of letermovir with voriconazole (a CYP2C19 substrate) results in significantly
decreased voriconazole plasma concentrations, indicating that letermovir is an inducer of CYP2C19.
CYP2C9 is likely also induced. Letermovir has the potential to decrease the exposure of CYP2C9
and/or CYP2C19 substrates potentially resulting in subtherapeutic levels.
-Examples of such medicinal products include warfarin, voriconazole, diazepam, lansoprazole,
omeprazole, esomeprazole, pantoprazole, tilidine, tolbutamide (see Table 2).
The effect is expected to be less pronounced for oral letermovir without cyclosporine, than intravenous
letermovir with or without cyclosporine, or oral letermovir with cyclosporine. This needs to be
considered when the letermovir regimen is changed during treatment with a CYP2C9 or CYP2C19
substrate. See also general information on induction above regarding time courses of the interaction.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) esomeprazole (HOS-087944) pantoprazole (HOS-085167) diazepam (HOS-085904) voriconazole (HOS-084524) tilidine (HOS-139791) cyclosporine (HOS-084512) warfarin (HOS-085950) tolbutamide (HOS-086568) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage 9a2733477e121be76b88fbc86a7699a813c89024f9b20d27ed3a29d6201fbfae · Zeichen 7024–8008 im Abschnitt
Wechselwirkungen · Prevymis
PREVYMIS 20 mg granules in sachet PREVYMIS 120 mg granules in sachet · Abschnitt 4.5 · PDF-Seite 74
HOS-139929 · Präparat HOS-098408
Medicinal products metabolised by CYP2C9 and/or CYP2C19
Co-administration of letermovir with voriconazole (a CYP2C19 substrate) results in significantly
decreased voriconazole plasma concentrations, indicating that letermovir is an inducer of CYP2C19.
CYP2C9 is likely also induced. Letermovir has the potential to decrease the exposure of CYP2C9
and/or CYP2C19 substrates potentially resulting in subtherapeutic levels.
-Examples of such medicinal products include warfarin, voriconazole, diazepam, lansoprazole,
omeprazole, esomeprazole, pantoprazole, tilidine, tolbutamide (see Table 2).
The effect is expected to be less pronounced for oral letermovir without cyclosporine, than intravenous
letermovir with or without cyclosporine, or oral letermovir with cyclosporine. This needs to be
considered when the letermovir regimen is changed during treatment with a CYP2C9 or CYP2C19
substrate. See also general information on induction above regarding time courses of the interaction.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) esomeprazole (HOS-087944) pantoprazole (HOS-085167) diazepam (HOS-085904) voriconazole (HOS-084524) tilidine (HOS-139791) cyclosporine (HOS-084512) warfarin (HOS-085950) tolbutamide (HOS-086568) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage 9a2733477e121be76b88fbc86a7699a813c89024f9b20d27ed3a29d6201fbfae · Zeichen 7003–7987 im Abschnitt
Wechselwirkungen · Prasugrel Viatris (previously Prasugrel Mylan)
Prasugrel Viatris 5 mg film-coated tablets Prasugrel Viatris 10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-289504 · Präparat HOS-287204
Medicinal products that elevate gastric pH
Daily co administration of ranitidine (an H2 blocker) or lansoprazole (a proton pump inhibitor) did not
change the prasugrel active metabolite’s AUC and Tmax , but decreased the Cmax by 14% and 29%,
respectively. In the phase 3 clinical study, prasugrel was administered without regard to co
administration of a proton pump inhibitor or H 2 blocker. Administration of the 60 mg prasugrel
loading dose without concomitant use of proton pump inhibitors may provide most rapid onset of
action.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) ranitidine (HOS-085660) prasugrel (HOS-112066)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-02T11:47:00Z · SHA-256 7beae4b62105463f66fe595711eeda85a009d76c25474934e99431a1a655597e · Passage 5495872185738638965eed3a35d38a7eece652d8bb29d7ec15a13d37a75c8684 · Zeichen 2494–3027 im Abschnitt
Wechselwirkungen · Rozlytrek
Rozlytrek 100 mg hard capsules Rozlytrek 200 mg hard capsules · Abschnitt 4.5 · PDF-Seite 11
HOS-142991 · Präparat HOS-098918
Effect of medicinal products that increase gastric pH on entrectinib
Co-administration of a proton pump inhibitor (PPI), lansoprazole with a single 600 mg entrectinib
dose reduced entrectinib AUC by 25% and Cmax by 23%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-27T15:44:00Z · SHA-256 dd56cb496d4ec02972235ebd05e62294b444e36302865842fe46e147734ef2b5 · Passage fd6a18f4e512f6a9e6912e954c06dc10654d3ced61eb1305c2ec6db0118b648c · Zeichen 4665–4884 im Abschnitt
Wechselwirkungen · Rozlytrek
Rozlytrek 50 mg film-coated granules in sachet · Abschnitt 4.5 · PDF-Seite 42
HOS-143058 · Präparat HOS-098918
Effect of medicinal products that increase gastric pH on entrectinib
Co-administration of a proton pump inhibitor (PPI), lansoprazole with a single 600 mg entrectinib
dose reduced entrectinib AUC by 25% and Cmax by 23%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-27T15:44:00Z · SHA-256 dd56cb496d4ec02972235ebd05e62294b444e36302865842fe46e147734ef2b5 · Passage fd6a18f4e512f6a9e6912e954c06dc10654d3ced61eb1305c2ec6db0118b648c · Zeichen 4663–4882 im Abschnitt
Wechselwirkungen · Clopidogrel / Acetylsalicylic acid Viatris (previously Clopidogrel / Acetylsalicylic acid Mylan)
Clopidogrel/Acetylsalicylic acid Viatris 75 mg/75 mg film-coated tablets Clopidogrel/Acetylsalicylic acid Viatris 75 mg/100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-291848 · Präparat HOS-287566
Less pronounced reductions of metabolite exposure has been observed with pantoprazole or
lansoprazole.
The plasma concentrations of the active metabolite was 20% reduced (loading dose) and 14% reduced
(maintenance dose) during concomitant treatment with pantoprazole 80 mg once daily. This was
associated with a reduction of the mean inhibition of platelet aggregation by 15% and 11%,
respectively. These results indicate that clopidogrel can be administered with pantoprazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T14:17:00Z · SHA-256 7df4afe5044cdc066630841d050ab3f3c0a18c3ffa6368461cdb4efae674000a · Passage 8741959ca26ef1991d9f10cb8dc0408f0677a8d230580e185084c52e76eb6108 · Zeichen 5261–5738 im Abschnitt
Wechselwirkungen · Emcitate
Emcitate 350 microgram dispersible tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-145386 · Präparat HOS-099344
Proton pump inhibitors (PPIs)
Co-administration with PPIs may cause a decrease in the absorption of the thyroid hormones, due to
the increase of the intragastric pH caused by PPIs such as omeprazole, esomeprazole, pantoprazole,
rabeprazole and lansoprazole. Serum concentrations of T3 should be monitored and dose adjustment
of tiratricol considered when initiating, changing or discontinuing PPI treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) rabeprazole (HOS-114843) esomeprazole (HOS-087944) pantoprazole (HOS-085167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-11T10:55:11Z · SHA-256 f1406017bf71ca6ed21c19c56ad9b2f42db03a6c0c95a8b1a995b810587719f2 · Passage f801ef17438c9ed33d30d077ff1f9b5a47ec71bff15f7bcd4ca8fef0f960bd66 · Zeichen 1031–1438 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.